New shorter chemo combo shows promise for hodgkin lymphoma
NCT ID NCT07002216
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a shortened course of a drug combination called BrECADD for people with advanced Hodgkin lymphoma. The goal is to see if a shorter treatment can still control the cancer while reducing side effects. About 48 adults aged 18 to 60 will receive up to four cycles of the therapy. The study also looks at a blood test to track how well the treatment is working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD)
What this could lead to
If successful, this could offer a shorter, more tolerable chemotherapy regimen for advanced Hodgkin lymphoma, potentially reducing side effects while maintaining effectiveness.
What could go wrong
This is a small, early-phase trial with only 48 participants, so results may not apply to all patients. The drug combination still carries significant side effects, and it is not yet known if it works better than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33146, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact